ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

FHS
July 21, 2023
11:04 am

Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

Medical device firms brace for effect of White House tariffs

Medical device companies are preparing for the impact of new tariffs on Mexico and Canada and another hike on China tariffs. The changes, which went

March 4, 2025

Gum disease and tooth loss linked to brain shrinkage

Taking good care of your teeth may be linked to better brain health, according to a study published in the July 5, 2023, online issue

July 6, 2023

Understanding ICH Guideline Q14 – Pharmaceutical Technology

Q14 is a new guideline detailing the elements of minimal and enhanced approaches for analytical procedure development. While the traditional minimal development approach remains valid,

August 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.